Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Masatoshi KudoPeter Robert GalleJosep M LlovetRichard S FinnArndt VogelKenta MotomuraEric AssenatPhilippe MerleGiovanni BrandiBruno DanieleTakuji OkusakaJiří TomášekChristophe BorgVincenzo DadduzioManabu MorimotoMarc PrachtMin-Hua JenNora Drove UbrevaRyan C WidauKenta ShinozakiReigetsu YoshikawaAndrew X ZhuPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
In this post-hoc analysis, ramucirumab showed a survival benefit across age subgroups with a tolerable safety profile, supporting its use in advanced HCC with elevated AFP, irrespective of age, including ≥75 years.
Keyphrases